vs

Side-by-side financial comparison of Regional Management Corp. (RM) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Regional Management Corp. is the larger business by last-quarter revenue ($167.3M vs $151.7M, roughly 1.1× Tarsus Pharmaceuticals, Inc.). Regional Management Corp. runs the higher net margin — 6.8% vs -5.5%, a 12.3% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 9.4%). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 8.2%).

Millennium Management LLC is an investment management firm with a multistrategy hedge fund offering. It is one of the world's largest alternative asset management firms with $83.4 billion assets under management as of January 2026. The firm operates in America, Europe and Asia. As of 2022, Millennium had posted the fourth highest net gains of any hedge fund since its inception in 1989.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

RM vs TARS — Head-to-Head

Bigger by revenue
RM
RM
1.1× larger
RM
$167.3M
$151.7M
TARS
Growing faster (revenue YoY)
TARS
TARS
+119.0% gap
TARS
128.4%
9.4%
RM
Higher net margin
RM
RM
12.3% more per $
RM
6.8%
-5.5%
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
8.2%
RM

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
RM
RM
TARS
TARS
Revenue
$167.3M
$151.7M
Net Profit
$11.4M
$-8.4M
Gross Margin
Operating Margin
-5.3%
Net Margin
6.8%
-5.5%
Revenue YoY
9.4%
128.4%
Net Profit YoY
62.7%
63.8%
EPS (diluted)
$1.18
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RM
RM
TARS
TARS
Q1 26
$167.3M
Q4 25
$169.7M
$151.7M
Q3 25
$165.5M
$118.7M
Q2 25
$157.4M
$102.7M
Q1 25
$153.0M
$78.3M
Q4 24
$154.8M
$66.4M
Q3 24
$146.3M
$48.1M
Q2 24
$143.0M
$40.8M
Net Profit
RM
RM
TARS
TARS
Q1 26
$11.4M
Q4 25
$12.9M
$-8.4M
Q3 25
$14.4M
$-12.6M
Q2 25
$10.1M
$-20.3M
Q1 25
$7.0M
$-25.1M
Q4 24
$9.9M
$-23.1M
Q3 24
$7.7M
$-23.4M
Q2 24
$8.4M
$-33.3M
Operating Margin
RM
RM
TARS
TARS
Q1 26
Q4 25
9.5%
-5.3%
Q3 25
11.5%
-12.2%
Q2 25
8.6%
-21.6%
Q1 25
6.0%
-33.5%
Q4 24
8.2%
-36.8%
Q3 24
6.9%
-52.3%
Q2 24
7.8%
-81.6%
Net Margin
RM
RM
TARS
TARS
Q1 26
6.8%
Q4 25
7.6%
-5.5%
Q3 25
8.7%
-10.6%
Q2 25
6.4%
-19.8%
Q1 25
4.6%
-32.1%
Q4 24
6.4%
-34.8%
Q3 24
5.2%
-48.7%
Q2 24
5.9%
-81.6%
EPS (diluted)
RM
RM
TARS
TARS
Q1 26
$1.18
Q4 25
$1.30
$-0.17
Q3 25
$1.42
$-0.30
Q2 25
$1.03
$-0.48
Q1 25
$0.70
$-0.64
Q4 24
$0.96
$-0.57
Q3 24
$0.76
$-0.61
Q2 24
$0.86
$-0.88

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RM
RM
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$417.3M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$375.8M
$343.4M
Total Assets
$2.1B
$562.2M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RM
RM
TARS
TARS
Q1 26
Q4 25
$417.3M
Q3 25
$401.8M
Q2 25
$381.1M
Q1 25
$407.9M
Q4 24
$291.4M
Q3 24
$317.0M
Q2 24
$323.6M
Total Debt
RM
RM
TARS
TARS
Q1 26
Q4 25
$1.6B
$72.4M
Q3 25
$1.6B
$72.3M
Q2 25
$1.5B
$72.1M
Q1 25
$1.5B
$72.0M
Q4 24
$1.5B
$71.8M
Q3 24
$1.4B
$71.7M
Q2 24
$1.4B
$71.6M
Stockholders' Equity
RM
RM
TARS
TARS
Q1 26
$375.8M
Q4 25
$373.1M
$343.4M
Q3 25
$371.9M
$335.1M
Q2 25
$363.0M
$332.6M
Q1 25
$357.9M
$342.5M
Q4 24
$357.1M
$224.5M
Q3 24
$352.9M
$237.5M
Q2 24
$344.9M
$252.2M
Total Assets
RM
RM
TARS
TARS
Q1 26
$2.1B
Q4 25
$2.1B
$562.2M
Q3 25
$2.0B
$534.6M
Q2 25
$2.0B
$495.0M
Q1 25
$1.9B
$500.8M
Q4 24
$1.9B
$377.0M
Q3 24
$1.8B
$376.3M
Q2 24
$1.8B
$376.8M
Debt / Equity
RM
RM
TARS
TARS
Q1 26
Q4 25
4.40×
0.21×
Q3 25
4.23×
0.22×
Q2 25
4.14×
0.22×
Q1 25
4.11×
0.21×
Q4 24
4.12×
0.32×
Q3 24
3.94×
0.30×
Q2 24
3.98×
0.28×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RM
RM
TARS
TARS
Operating Cash FlowLast quarter
$19.3M
Free Cash FlowOCF − Capex
$13.0M
FCF MarginFCF / Revenue
8.6%
Capex IntensityCapex / Revenue
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RM
RM
TARS
TARS
Q1 26
Q4 25
$309.1M
$19.3M
Q3 25
$86.7M
$18.3M
Q2 25
$78.7M
$-29.4M
Q1 25
$63.7M
$-20.7M
Q4 24
$268.9M
$-22.2M
Q3 24
$75.1M
$-8.7M
Q2 24
$71.5M
$-14.4M
Free Cash Flow
RM
RM
TARS
TARS
Q1 26
Q4 25
$304.3M
$13.0M
Q3 25
$85.7M
$16.3M
Q2 25
$77.6M
$-30.4M
Q1 25
$62.4M
$-21.2M
Q4 24
$263.9M
$-22.3M
Q3 24
$73.8M
$-8.9M
Q2 24
$70.3M
$-15.4M
FCF Margin
RM
RM
TARS
TARS
Q1 26
Q4 25
179.3%
8.6%
Q3 25
51.8%
13.8%
Q2 25
49.3%
-29.6%
Q1 25
40.8%
-27.1%
Q4 24
170.4%
-33.5%
Q3 24
50.4%
-18.6%
Q2 24
49.1%
-37.8%
Capex Intensity
RM
RM
TARS
TARS
Q1 26
Q4 25
2.8%
4.2%
Q3 25
0.6%
1.6%
Q2 25
0.6%
1.0%
Q1 25
0.8%
0.8%
Q4 24
3.3%
0.1%
Q3 24
0.9%
0.6%
Q2 24
0.8%
2.5%
Cash Conversion
RM
RM
TARS
TARS
Q1 26
Q4 25
23.94×
Q3 25
6.04×
Q2 25
7.76×
Q1 25
9.09×
Q4 24
27.13×
Q3 24
9.80×
Q2 24
8.47×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons